Theravance Inc. (THRX) Stock Quote

Detailed Quote for Theravance Inc. (THRX)

After Hours: $ 16.53

0.00 (0.00%)

Volume: 100

4:50 PM EST Feb 10, 2012

close 52 Week Information

52 Week High

April 29, 2011

Close: 28.95

52 Week Low

January 9, 2012

Close: 12.91

Today

Last Price
16.53

Change $
0.82

Change %
4.73%

Tick
N/A

Bid
15.65

Bid Size
100

Ask
17.58

Ask Size
100

Open
16.61

High
16.85

Low
15.69

Prev Close
17.35

Last Trade
4:00

Volume
857.1 k

52 Wk Hi
28.95

52 Wk Low
12.91

Market Cap
1.41 b

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
85,128,202

EPS (TTM)
-1.21

PE Ratio
N/A

close Exchange Information Listed On NASDAQ (NSD) Exchange
NSD

News and Media for Theravance Inc. (THRX)

Sector News | Topic News

News for THRX

Thu, Feb 09, 2012

4:05 PM

Theravance Reports Fourth Quarter and Full Year 2011 Financial Results - Marketwire

Wed, Feb 01, 2012

4:05 PM

Theravance to Present at Investor Conferences in February 2012 - Marketwire

Thu, Jan 26, 2012

4:05 PM

Theravance to Report Fourth Quarter and Full Year 2011 Financial Results on February 9, 2012 - Marketwire

Mon, Jan 09, 2012

12:35 PM

Live Press Briefing on Findings of Biomedical Industry CEO Survey - PR Newswire

2:00 AM

GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies for Once-Daily Relovair(TM)* in COPD and Asthma - Marketwire

Fri, Jan 06, 2012

5:15 PM

Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV(R) (telavancin) for Injection - Marketwire

Wed, Dec 28, 2011

4:05 PM

Theravance to Present at the 30th Annual J.P. Morgan Healthcare Conference - Marketwire

Mon, Dec 12, 2011

8:01 AM

Theravance Announces Initiation of Phase 2 Study With Its MARIN Compound, TD-9855, for the Treatment of ADHD - Marketwire

Mon, Nov 14, 2011

4:05 PM

Theravance Announces Positive Results From a Phase 2a Study of Its LAMA Candidate, TD-4208, for the Treatment of COPD - Marketwire

Tue, Nov 01, 2011

4:05 PM

Theravance to Present at Investor Conferences in November 2011 - Marketwire

Thu, Oct 27, 2011

4:05 PM

Theravance Reports Third Quarter 2011 Financial Results - Marketwire

Wed, Oct 19, 2011

4:30 PM

Theravance Announces Presentation of GSK Phase 2 Data for LAMA (GSK573719) at CHEST 2011 - Marketwire

Thu, Oct 13, 2011

4:11 PM

Theravance to Report Third Quarter 2011 Financial Results on October 27, 2011 - Marketwire

Thu, Sep 15, 2011

3:01 AM

Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA - Marketwire

Wed, Aug 24, 2011

4:06 PM

Theravance to Present at Investor Conferences in September 2011 - Marketwire

Thu, Jul 28, 2011

4:05 PM

Theravance Reports Second Quarter 2011 Financial Results - Marketwire

Thu, Jul 14, 2011

4:05 PM

Theravance to Report Second Quarter 2011 Financial Results on July 28, 2011 - Marketwire

Thu, Jun 02, 2011

7:00 AM

GSK and Theravance Announce Results of Two Pivotal Phase III Studies for Relovair(TM) in COPD - Marketwire

Tue, May 24, 2011

4:10 PM

Theravance to Present at Investor Conferences in June 2011 - Marketwire

Fri, May 20, 2011

9:15 AM

Astellas and Theravance Receive Positive Opinion From CHMP for European Approval of VIBATIV(TM) for Nosocomial Pneumonia Caused by MRSA - Marketwire

More News for THRX >>

Tags for Theravance Inc.

Research stocks or mutual funds related to Theravance Inc. by keywords or tags. Find companies that have a similar focus to THRX. The keywords below have been associated to THRX by either user submission or electronic means.

pharmaceutical articles manufacturing contracts pharmaceutical industry strategy pharmaceutical publication pharmaceutical market pharmaceuticals companies generic pharmaceutical medical product development pharmaceutical research and development recurring bacterial vaginosis pharmaceutical manufacturing company pharma marketing medical device contract manufacturing pharma manufacturing pharma license pharmaceutical supply chain novartis pharmaceuticals pharmaceutical cro pharma consulting theravance warranty liability pharmaceutical sales pharma pharmaceutical distributors contract amendments biotech corporation pharmaceutical development pharmaceutical production pharmaceutical magazine pharmaceutical consultant biotech Drugs pharmaceutical manufacturing software liability contracts pharmaceutical manufacturing pharmaceutical formulation contract manufacturing pharmaceutical article pfizer pharmaceuticals contract pharmaceutical pharmaceutical consulting pharmaceutical events research biotech pharmaceutical industry biotech contract pharmaceutical strategy patent research healthcare contract pharmaceutical advances pharmaceutical distributor